United States Allergy Immunotherapy Market Insights Forecasts to 2033

• The U.S. Allergy Immunotherapy Market Size was valued at USD 253 Million in 2023.
• The Market Size is Growing at a CAGR of 10.39% from 2023 to 2033
• The U.S. Allergy Immunotherapy Market Size is Expected to Reach USD 680 Million by 2033

The U.S. Allergy Immunotherapy Market Size is Anticipated to Exceed USD 680 Million by 2033, growing at a CAGR of 10.39% from 2023 to 2033.

Market Overview

Allergy immunotherapy or allergen desensitization is the repeated administration of specific allergens to an individual suffering from immunoglobulin E (IgE)-mediated conditions. These therapies are administered in order to protect against the inflammatory reactions and allergic symptoms caused due to exposure to allergens such as house mites, pollens, insects, and others. The United States is witnessing a sharp rise in the cases of various types of allergies every year. With the increasingly mounting burden of allergies across the country, there is an ever-growing need for treatments such as immunotherapy. Roughly 25.7% of the adult population in the country had seasonal allergies in the year 2021, according to the 2023 data from the Centers for Disease Control and Prevention. Some drivers of the increased adoption of allergy immunotherapy products within the country include awareness by the population about bettering their health and managing allergies, among others, besides product approval by regulatory bodies.

Report Coverage

This research report categorizes the market for the US allergy immunotherapy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States allergy immunotherapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the U.S. allergy immunotherapy market.

Driving Factors

The growing incidences of allergies in the country are the leading factor that triggers the demand for allergy immunotherapy drugs. Asthma and Allergy Foundation of America projects that about 81.0 million people have had hay fever at some point in 2021 in the U.S. Moreover, the rising government initiatives for proper handling of allergic symptoms are enhancing patient intake of these drugs. Apart from that, the new product launches from the manufacturers to meet up with the ever-growing demand in the market will fuel the U.S. allergy immunotherapy market in the near future.

Restraining Factors

A few disadvantages of immunotherapy products, such as low efficiency, inconvenience caused to the patients, and the high cost of the treatment regimen as compared to other alternative drugs available, is likely to hinder the market growth in the U.S. Moreover, the complications associated with immunotherapy include reactions at the injection site, anaphylaxis, and others that limit their adoption.

Market Segmentation

The US allergy immunotherapy market share is classified into type and application.

• The subcutaneous immunotherapy segment is expected to hold a significant market share through the forecast period.

The United States allergy immunotherapy market is segmented by type into subcutaneous immunotherapy and sublingual immunotherapy. Among these, the subcutaneous immunotherapy segment is expected to hold a significant market share through the forecast period. SCIT is still recognized as the gold standard treatment for allergies with better efficiency than any product from SLIT. Even more product launches boosted the market in the U.S. An article by NCBI published in 2021, states that subcutaneous immunotherapy is indeed 80% effective for allergy treatment compared to SLIT.

• The allergic rhinitis segment is expected to dominate the US allergy immunotherapy market during the projected period.

Based on the application, the United States allergy immunotherapy market is divided into allergic rhinitis, allergic asthma, and others. Among these, the allergic rhinitis segment is expected to dominate the US allergy immunotherapy market during the projected period. Factors that are driving up the market are the growing prevalence of allergic rhinitis in the country and the introduction of new products under development for allergic rhinitis. For instance, in January 2023, the US FDA approved Odactra, which is a sublingual immunotherapy for treatment against house dust mite-induced allergic rhinitis.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States allergy immunotherapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• ALK
• Stallergenes Greer
• Allergy Therapeutics
• HollisterStier Allergy
• Dermapharm Holding SE
• HAL Allergy B.V.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2021, ALK formed a digital venture collaboration with the New York Government in its attempt to persuade more allergy patients in the U.S. to buy SLIT tablets from ALK.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States allergy immunotherapy market based on the below-mentioned segments:

United States Allergy Immunotherapy Market, By Type

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

United States Allergy Immunotherapy Market, By Application

• Allergic Rhinitis
• Allergic Asthma
• Others